Last updated: September 16, 2026
Bumetanide is an established generic loop diuretic with no meaningful branded exclusivity barrier. Commercial value lies in differentiated dosage forms, excipient-enabled administration, supply reliability, and targeted clinical niches rather than in the active pharmaceutical ingredient itself. The strongest opportunities are an alcohol-free oral liquid, a taste-masked pediatric formulation, a rapidly disintegrating tablet, and hospital-ready injectable presentations.
What is the current FDA regulatory and commercial status of bumetanide?
Bumetanide is an FDA-approved loop diuretic indicated for edema associated with congestive heart failure, hepatic disease, and renal disease, including nephrotic syndrome. It is marketed primarily as oral tablets and an injectable solution. The reference product is Bumex, originally approved under NDA 018225. Generic bumetanide products are approved through the ANDA pathway.[1,2]
| Attribute |
Bumetanide status |
| Active ingredient |
Bumetanide |
| Pharmacologic class |
Loop diuretic |
| Main branded reference |
Bumex |
| FDA pathway |
NDA and multiple ANDAs |
| Common oral strengths |
0.5 mg, 1 mg, 2 mg |
| Injectable strength |
Commonly 0.25 mg/mL |
| Primary dosage forms |
Tablets and injection |
| Route of administration |
Oral, intravenous, intramuscular |
| Therapeutic use |
Edema and fluid overload |
| Market structure |
Mature generic market |
| Current branded exclusivity |
No material current exclusivity identified in standard FDA product listings |
| Main commercial constraint |
Low unit price and established generic competition |
The drug is potent, with a typical oral dose materially lower than doses used for furosemide. Dose accuracy, content uniformity, taste, and safe handling therefore matter more than bulk excipient cost.
What excipients are used in bumetanide tablets and injection?
Commercial bumetanide tablets generally use conventional solid-dose excipients. The exact formulation differs by manufacturer and approved ANDA. Labeling for generic products commonly identifies lactose or another diluent, microcrystalline cellulose, starch, colloidal silicon dioxide, talc, and magnesium stearate.[3-6]
Bumetanide injection generally contains sodium chloride, water for injection, and pH-adjusting agents such as sodium hydroxide or hydrochloric acid, depending on the product. The formulation is designed for a small-volume parenteral presentation and must control pH, particulate matter, sterility, and chemical stability.[7]
| Dosage form |
Typical excipient functions |
Commercial formulation issue |
| Immediate-release tablet |
Dilution, compression, disintegration, lubrication, flow control |
Very low drug load can create content-uniformity risk |
| Oral liquid |
Solubilization or suspension, buffering, preservation, viscosity control, taste masking |
Bumetanide solubility and palatability can limit stability |
| Injection |
Tonicity, pH adjustment, solvent system |
Parenteral compatibility and stability are decisive |
| Orally disintegrating tablet |
Superdisintegration, wicking, taste masking, direct compression |
Bitter taste and low dose uniformity require tight process control |
| Modified-release tablet |
Matrix or coating polymers |
May conflict with the drug’s short half-life and need for predictable diuresis |
Excipient selection should start with the product’s dose, route, target population, and stability profile. A generic copy of an immediate-release tablet should avoid unnecessary excipient novelty because any change can increase formulation-development and bioequivalence risk.
What are the key physicochemical excipient constraints for bumetanide?
Bumetanide is a weakly acidic, aromatic sulfonamide loop diuretic with limited intrinsic aqueous solubility. Its solubility improves under alkaline conditions, but excessive pH adjustment can create tolerability, stability, container-closure, and administration problems.[8,9]
The main formulation constraints are:
- Low-dose content uniformity. A 0.5 mg tablet contains a small quantity of active ingredient relative to the excipient mass. Ordered mixing, geometric dilution, and segregation control are important.
- pH-dependent solubility. Alkaline solubilization may support liquid or injectable development but can increase chemical and container-compatibility risk.
- Bitter taste. This is material for pediatric, geriatric, and orally disintegrating products.
- Short pharmacokinetic duration. Bumetanide has a relatively short plasma half-life, generally about one to two hours, although the pharmacodynamic effect lasts longer.[8]
- Dose-related electrolyte effects. Excipient innovation cannot compensate for the need for precise dosing and clear labeling.
- Moisture and lubricant sensitivity. Excess magnesium stearate or hydrophobic processing can slow dissolution in a low-dose formulation.
Which excipient strategy is best for generic bumetanide tablets?
The lowest-risk strategy is an immediate-release, lactose- or cellulose-based tablet that closely follows established generic performance. The formulation should prioritize rapid disintegration, robust content uniformity, and manufacturing simplicity.
Recommended baseline formulation
A practical development platform may include:
- Microcrystalline cellulose or lactose monohydrate as the principal diluent.
- Croscarmellose sodium, crospovidone, or sodium starch glycolate as the superdisintegrant.
- Colloidal silicon dioxide for flow improvement.
- Low-concentration magnesium stearate or sodium stearyl fumarate as lubricant.
- Optional low-level starch as binder or disintegrant.
Sodium stearyl fumarate may be commercially attractive where magnesium stearate causes dissolution variability or tablet ejection problems. It can also support a more hydrophilic formulation, although its use requires comparative dissolution and stability work.
A direct-compression approach may reduce processing steps, but roller compaction or wet granulation can provide better blend uniformity where the active is difficult to distribute. The correct choice depends on particle size, density, electrostatic behavior, and potency assay variability.
What commercial opportunities exist for a bumetanide oral liquid?
An oral liquid is the clearest dosage-form opportunity because bumetanide is commonly used in patients who have difficulty swallowing tablets. Potential users include pediatric patients, older adults, patients receiving enteral nutrition, and patients with advanced renal or cardiac disease.
The commercial product should ideally be:
- Alcohol-free.
- Sugar-free or low-sugar.
- Ready-to-use.
- Available in a calibrated oral syringe.
- Stable at room temperature.
- Compatible with feeding tubes.
- Palatable at the relevant dose volume.
Solubilized versus suspension-based liquid
A solubilized liquid may provide dose uniformity and tube compatibility but could require alkaline pH, cosolvents, surfactants, or complexation. Those features can increase regulatory and tolerability risk.
A suspension may permit a more neutral pH and reduce chemical stress. Its weaknesses are sedimentation, redispersibility, dose variability, and the need for “shake well” instructions.
Potential excipient systems include:
| Objective |
Candidate excipient categories |
| Wetting |
Polysorbates, poloxamers, glycerin |
| Viscosity and suspension |
Xanthan gum, hypromellose, microcrystalline cellulose-carboxymethylcellulose |
| Buffering |
Citrate, phosphate, or other low-capacity buffer systems |
| Preservation |
Parabens, benzoates, sorbates, or alternative preservative systems |
| Sweetening |
Sucralose, acesulfame potassium, sorbitol, or sugar-based systems |
| Taste masking |
Ion-exchange resins, cyclodextrins, polymeric coating, flavor systems |
The formulation should avoid high ethanol content and excessive propylene glycol if the target population includes children, frail older adults, or patients with compromised renal or hepatic function.
How strong is the opportunity for a bumetanide orally disintegrating tablet?
An orally disintegrating tablet could address swallowing difficulty without requiring a liquid product. The principal challenge is taste. Bumetanide’s low dose is favorable for tablet size, but the bitter active may become more noticeable as the tablet disperses in the mouth.
A commercially viable ODT would likely require:
- A taste-masking layer or polymeric complex.
- Crospovidone or another fast disintegrant.
- Mannitol or a comparable mouthfeel excipient.
- A robust moisture barrier.
- Packaging in alu-alu blisters or another protective system.
- Dose uniformity controls suitable for a low-dose drug.
An ODT is more defensible than a conventional tablet from a product-positioning perspective, but the regulatory value depends on whether the sponsor pursues an ANDA, a 505(b)(2) application, or an abbreviated pathway available for the specific product design. The sponsor must establish that taste masking does not delay release or alter exposure.
What excipient strategy is appropriate for bumetanide injection?
The injectable product has less room for formulation differentiation because parenteral excipients face strict safety and compatibility requirements. The most commercially relevant improvements are presentation and handling rather than novel excipient chemistry.
Potential opportunities include:
- Ready-to-administer prefilled syringes.
- Unit-dose vials with standardized concentration.
- Premixed infusion bags where clinically justified.
- Preservative-free single-dose presentations.
- Low-sorption container-closure systems.
- Packaging optimized for emergency departments and intensive-care units.
The product must control pH, osmolality, particulate matter, sterility, extractables and leachables, and adsorption to glass, plastic, and syringe components. Alkaline formulations require particular attention to elastomer compatibility and container integrity.
A ready-to-use presentation may reduce medication-preparation errors and nursing labor. That commercial value can exceed the value of adding a new excipient to a conventional vial.
What formulation patents and patent barriers protect bumetanide products?
Bumetanide’s original composition-of-matter protection and initial product exclusivity expired long ago. The ordinary tablet and injection market is therefore exposed to generic competition. FDA Orange Book listings should be reviewed for current patent and exclusivity entries tied to each reference product and dosage form.[2]
| IP category |
Bumetanide assessment |
| Composition-of-matter patent |
Expired |
| Original product exclusivity |
Expired |
| Conventional tablet protection |
Generally weak absent a distinct formulation |
| Conventional injection protection |
Generally weak absent a distinct presentation or formulation |
| Method-of-use patents |
Limited commercial value where the indication is established and broadly generic |
| Liquid formulation patents |
Possible, but dependent on specific excipient, pH, stability, or dosing claims |
| ODT patents |
Possible for taste masking, disintegration, and packaging combinations |
| Manufacturing patents |
Possible for low-dose blending, granulation, or sterile processing |
| Orange Book leverage |
Likely limited for ordinary generic presentations |
A new formulation patent would need credible technical distinctions. Broad claims covering “bumetanide plus conventional excipients” would face validity and obviousness pressure. More defensible claims could focus on:
- A defined pH and solubilizer system.
- Long-term chemical stability.
- Specific taste-masking complexes.
- Improved feeding-tube delivery.
- A moisture-protective ODT architecture.
- A low-dose blending process that produces defined content-uniformity performance.
- A ready-to-administer sterile presentation with container-compatibility limitations.
When does bumetanide lose exclusivity, and what generic entry risks exist?
Bumetanide has already lost its original exclusivity. Generic entry is not the future risk; it is the existing market condition. The relevant risks for a new entrant are price compression, therapeutic interchangeability, shortage-driven purchasing volatility, and limited reimbursement differentiation.
Generic launch scenarios
| Launch model |
Commercial attractiveness |
Primary risk |
| Standard tablet |
Low to moderate |
Intense price competition |
| Oral solution |
Moderate to high |
Stability, taste, and preservative development |
| ODT |
Moderate |
Taste masking and bioequivalence |
| Ready-to-use injection |
Moderate to high |
Sterile manufacturing and hospital contracting |
| Prefilled syringe |
High in targeted settings |
Device and combination-product requirements |
| Compounded-style suspension converted to approved product |
Moderate |
Regulatory and stability burden |
| Veterinary-specific presentation |
Niche |
Limited volume and channel concentration |
Which companies are challenging or competing with bumetanide?
The competitive set consists mainly of generic manufacturers and contract manufacturers rather than branded innovators. Competition is based on:
- Lowest acquisition cost.
- Reliable supply.
- FDA manufacturing compliance.
- Injectable capacity.
- Shortage resilience.
- Packaging and unit-dose flexibility.
- Hospital and wholesaler contracts.
Because standard bumetanide tablets are therapeutically familiar, a new entrant without a supply, formulation, or channel advantage is unlikely to obtain durable pricing power. The strongest commercial position would combine a differentiated dosage form with dependable manufacturing.
How does bumetanide compare with furosemide and torsemide?
Bumetanide competes clinically with furosemide and torsemide. Furosemide has broader generic availability and a larger installed base. Torsemide has attracted interest in chronic heart-failure management because of its pharmacokinetic profile and oral dosing characteristics. Bumetanide’s main advantages are potency, availability in oral and injectable forms, and utility where predictable loop-diuretic dosing is needed.[8,10]
| Factor |
Bumetanide |
Furosemide |
Torsemide |
| Generic maturity |
High |
Very high |
High |
| Oral potency |
High |
Lower per milligram |
High |
| Injectable use |
Established |
Established |
More limited by product |
| Shortage opportunity |
Targeted |
Broad but crowded |
Targeted |
| Pediatric liquid opportunity |
Meaningful |
Larger competitive field |
More limited |
| Differentiated formulation space |
Moderate |
Crowded |
Moderate |
| Price pressure |
High |
Very high |
High |
An excipient supplier can therefore pursue bumetanide as part of a loop-diuretic platform rather than as a single-product project. Shared taste-masking, liquid, ODT, and sterile-fill technologies may support line extensions across all three active ingredients.
What licensing and partnership opportunities exist?
The most practical deals involve formulation platforms, manufacturing capacity, and hospital distribution.
Potential transaction structures include:
- Licensing a stable, alcohol-free bumetanide oral liquid to a generic company with pediatric or long-term-care distribution.
- Supplying a proprietary taste-masking system under a formulation-services agreement.
- Co-developing a prefilled injectable product with a sterile manufacturer.
- Licensing low-dose direct-compression technology for bumetanide and other potent generic APIs.
- Acquiring or partnering for an ANDA-ready dosage form with established bioequivalence data.
- Supplying specialty excipients under a dual-source arrangement to reduce shortage exposure.
The strongest partner would have an existing FDA-compliant facility, generic regulatory capability, and access to hospital, long-term-care, or specialty-pharmacy channels.
What revenue exposure and market size should investors expect?
Standard bumetanide tablets are a low-revenue, high-volume generic opportunity. Unit economics are constrained by multiple approved suppliers and limited clinical differentiation. Revenue exposure is more attractive in presentations that solve administration or procurement problems.
Potential value pools are concentrated in:
- Pediatric and dysphagia-friendly oral liquids.
- Hospital-ready injectable products.
- Shortage-resistant sterile supply.
- Unit-dose packaging.
- Specialty distribution to long-term-care facilities.
- Veterinary or compounded-use alternatives, subject to applicable regulatory requirements.
A differentiated product should be assessed on net price, annual treated population, contract duration, manufacturing yield, and channel concentration. Patent protection alone is unlikely to support a premium unless it corresponds to a demonstrable clinical or operational advantage.
Key Takeaways
- Bumetanide is a mature generic loop diuretic with expired original exclusivity.
- Conventional tablets face substantial price competition and have limited patent leverage.
- The strongest excipient opportunity is an alcohol-free, palatable, stable oral liquid.
- ODT development is feasible but requires effective taste masking and moisture protection.
- Injectable differentiation is more likely to come from prefilled or ready-to-administer packaging than from novel excipients.
- Low-dose content uniformity is a central manufacturing issue.
- Formulation patents must claim specific pH, stability, taste-masking, delivery, or manufacturing features.
- A bumetanide formulation platform can be extended to furosemide and torsemide.
- Licensing opportunities are strongest for excipient systems, sterile presentations, and supply-reliable generic products.
FAQs
Is bumetanide soluble enough for a ready-to-use oral solution?
Bumetanide has limited intrinsic aqueous solubility. A true solution may require pH adjustment, cosolvents, surfactants, complexation, or another solubilization approach. A suspension may be simpler but requires strong control of redispersibility and dose uniformity.
Which excipients are most suitable for masking bumetanide taste?
Ion-exchange resins, cyclodextrins, polymeric coating systems, and carefully selected sweetener-flavor combinations are the main candidates. The system must preserve dissolution and bioavailability.
Can bumetanide be formulated as a sustained-release product?
It can be formulated technically, but the commercial rationale is uncertain. The short half-life and need for predictable diuretic response may favor immediate-release delivery. A modified-release product would require a clear clinical or adherence advantage.
Does bumetanide have biosimilar competition?
No. Bumetanide is a small-molecule drug, so competition proceeds through generic drug pathways rather than biosimilar regulation.
What is the best patent strategy for a new bumetanide product?
The strongest strategy is a narrow formulation or manufacturing patent tied to measurable performance, such as long-term stability, improved taste masking, feeding-tube delivery, low-dose content uniformity, or a ready-to-administer sterile presentation.
References
- U.S. Food and Drug Administration. (n.d.). Bumex: Prescribing information.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations.
- DailyMed. (n.d.). Bumetanide tablet: Product labeling. National Library of Medicine.
- DailyMed. (n.d.). Bumetanide tablet, USP: Inactive ingredients and labeling. National Library of Medicine.
- U.S. Pharmacopeia. (2024). Bumetanide monograph. United States Pharmacopeial Convention.
- U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
- DailyMed. (n.d.). Bumetanide injection: Product labeling. National Library of Medicine.
- Brater, D. C. (1998). Diuretic therapy. New England Journal of Medicine, 339(6), 387-395.
- National Center for Biotechnology Information. (n.d.). PubChem compound summary: Bumetanide.
- Ellison, D. H. (2019). Clinical pharmacology in diuretic use. Clinical Journal of the American Society of Nephrology, 14(8), 1248-1257.
